Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function

American Heart Journal

Volumn 162, Issue 5, 2011, Pages

  Melloni, Chiara ^a   James, Stefan K ^b   White, Jennifer A ^a   Giugliano, Robert P ^c   Harrington, Robert A ^a   Huber, Kurt ^d   Tricoci, Pierluigi ^a   Armstrong, Paul W ^e   Van De Werf, Frans ^f   Montalescot, Gilles ^g   Califf, Robert M ^h   Newby, L Kristin ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WILHELMINEN HOSPITAL   (Austria)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EPTIFIBATIDE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

EID: 81255201367     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.08.020     Document Type: Article

References (27)

1. R.C. Becker, F.A. Spencer, and M. Gibson Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J 143 2002 753 759 (Pubitemid 34595330)
2. I.C. Gilchrist, S.D. Berkowitz, and T.D. Thompson Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience Am Heart J 144 2002 73 80 (Pubitemid 34734758)
3. D.D. Gretler, R. Guerciolini, and P.J. Williams Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function Clin Ther 26 2004 390 398 (Pubitemid 38460967)
4. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina) J Am Coll Cardiol 40 2002 1366 1374
5. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med 339 1998 436 443
6. J.E. Tcheng, J.D. Talley, and J.C. O'Shea Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) Am J Cardiol 88 2001 1097 1102 (Pubitemid 33043838)
7. I.C. Gilchrist, J.C. O'Shea, and T. Kosoglou Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention Circulation 104 2001 406 411 (Pubitemid 32678269)
8. Integrilin® (eptifibatide) [package insert] 2005 Schering Corporation Kenilworth, NJ
9. R.P. Giugliano, J.A. White, and C. Bode Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
10. R.P. Giugliano, L.K. Newby, and R.A. Harrington The EARLY ACS trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale Am Heart J 149 2005 994 1002 (Pubitemid 40848143)
11. European Medicines Agency European public assessment report for integrilin Revision 12, published 02/12/09. Available at: http://www.emea. europa.eu/humandocs/PDFs/EPAR/Integrilin/emea-combined-h230en.pdf Last accessed January 7, 2010
12. M.A. Cavender, S.V. Rao, and E.M. Ohman Major bleeding: management and risk reduction in acute coronary syndromes Expert Opin Pharmacother 9 2008 1869 1883
13. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
14. F.E.J. Harrell Regression modeling strategies with applications to linear models, logistic regression, and survival analysis 2001 Springer-Verlag New York
15. J. Al Suwaidi, D.N. Reddan, and K. Williams Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes Circulation 106 2002 974 980 (Pubitemid 34925333)
16. C.M. Gibson, R.L. Dumaine, and E.V. Gelfand Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials Eur Heart J 25 2004 1998 2005 (Pubitemid 39486018)
17. J.J. Santopinto, K.A. Fox, and R.J. Goldberg Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from GRACE Heart 89 2003 1003 1008 (Pubitemid 37046830)
18. R.V. Freeman, R.H. Mehta, and W. Al Badr Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors J Am Coll Cardiol 41 2003 718 724 (Pubitemid 36308375)
19. S.A. Spinler, K.W. Mahaffey, and D. Gallup Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY Int J Cardiol 144 2010 36 41
20. R. Dumaine, J.P. Collet, and M.L. Tanguy Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study) Am J Cardiol 94 2004 1543 1547 (Pubitemid 40268459)
21. S.G. Coca, H.M. Krumholz, and A.X. Garg Under-representation of renal disease in randomized controlled trials of cardiovascular disease JAMA 296 2006 1377 1384 (Pubitemid 44427424)
22. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
23. K.P. Alexander, A.Y. Chen, and M.T. Roe Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 2005 3108 3116 (Pubitemid 43016802)
24. A.J. Kirtane, G. Piazza, and S.A. Murphy Correlates of bleeding events among moderate-to-high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 2006 2374 2379 (Pubitemid 43866383)
25. K.P. Alexander, A.Y. Chen, and L.K. Newby Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative Circulation 114 2006 1380 1387
26. D.W. Mudrick, A.Y. Chen, and M.T. Roe Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative Am Heart J 160 2010 1072 1078
27. J.M. Teich, P.R. Merchia, and J.L. Schmiz Effects of computerized physician order entry on prescribing practices Arch Intern Med 160 2000 2741 2747